MUSK and myasthenia gravis: With the available data, all five (100%) MuSK autoantibody-positive patients in the rozanolizizumab 7 mg/kg group and all seven (100%) patients in the rozanolizizumab 10 mg/kg group were MG-ADL responders compared with one (14%) in seven in the placebo group.